gynecological cancer (ovarian cancer, endometrial cancer and uterine cervix cancer)
Conditions
Interventions
Palonosetron 0.75mg iv. prior to chemotherapy on Day1. Dexamethasone Day1 19.8mg or 9.9 mg iv. prior to chemotherapy. Day2 8.0mg orally or 6.6mg iv. Day3 8.0mg orally or 6.6mg iv.
Sponsors
West Japan Gynecologic Oncology Group
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1 more than Age 20 2 Patients with histologically proven gynecological cancer 3 No prior chemotherapy 4 Patient receiving carboplatin AUC5 6 5 Patient have enough organ function based on blood test within 8 days before registration Neutrophils more than 2,000 Platelets more than 100,000 AST and ALT less than 100 Serum creatinine less than1.5 6 ECOG performance status 0 2 7 Written informed consent
Exclusion criteria
Exclusion criteria: 1 Uncontrolled severe complication disease without cancers 2 Symptomatic brain metastasis 3 Epilepsy patient treated with antiepileptic agent, excluding being 4 Patient with massive pleural effusion or ascites to be required drainage 5 Intestinal paralysis or ileus 6 Grade 2 or more nausea and vomiting 7 Hypersensitivity for palonosetron and other 5 HT3 antagonist 8 Hypersensitivity for dexamethasone 9 Pregnant ,lactating woman or women who do not agree that we prevent conception 10 Patient with history of palonosetoron treatment 11 Patient without compliance of this study rule 12 Other patients who are unfit for the study as determined by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete control rate during the delay phase | — |
Countries
Japan
Contacts
Public ContactKimio Ushijima
Kurume University School of Medicine Department of Obstetrics and Gynecology
Outcome results
None listed